J&J Will Pay More Than $2.2 Billion to Settle U.S. Cases

Johnson & Johnson agreed to resolve criminal and civil probes into the marketing of Risperdal, an antipsychotic drug, and other medicines by paying more than $2.2 billion, one of the largest U.S. health-fraud penalties.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.